80%Confidence
0Views
SEC EDGARSource
2026-04-13Date
Summary
Spyre Therapeutics' filing suggests material corporate events for this biotechnology firm focused on inflammatory bowel disease. This may involve clinical development updates or partnership announcements in the competitive IBD treatment market.
Actionable: Check for clinical trial progress or strategic collaborations in the gastroenterology space.
AI Confidence: 80%
Data Points
companySpyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
form8-K
date2026-04-13
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now